Stockscreener 앱 받기
0.8481
1.98%
0.0152
전일 마감가:
$0.8329
열려 있는:
$0.8293
하루 거래량:
742.02K
Relative Volume:
0.07
시가총액:
$83.17M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+8.83%
1개월 성능:
+4.37%
6개월 성능:
-84.12%
1년 성능:
-74.02%
1일 변동 폭
$0.81
$0.8499
1주일 범위
$0.7001
$0.8596
52주 변동 폭
$0.64
$7.2904
Atyr Pharma Inc Stock (ATYR) Company Profile
명칭
Atyr Pharma Inc
전화
(858) 731-8389
주소
10240 SORRENTO VALLEY ROAD, SAN DIEGO
ATYR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATYR
Atyr Pharma Inc
|
0.8488 | 81.11M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.39 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
720.60 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.36 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
897.31 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.87 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-16 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-09-15 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-09-15 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-09-15 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-09-15 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-02-18 | 개시 | Leerink Partners | Outperform |
| 2025-01-06 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-10-04 | 개시 | Wells Fargo | Overweight |
| 2024-09-05 | 개시 | Jefferies | Buy |
| 2023-07-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-10-12 | 개시 | RBC Capital Mkts | Outperform |
| 2021-09-21 | 개시 | Piper Sandler | Overweight |
| 2021-05-10 | 개시 | Laidlaw | Buy |
| 2020-08-17 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-03-04 | 개시 | ROTH Capital | Buy |
| 2020-03-02 | 개시 | Oppenheimer | Outperform |
| 2018-02-14 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2017-09-07 | 개시 | Piper Jaffray | Overweight |
| 2016-12-13 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2015-12-16 | 개시 | Citigroup | Neutral |
| 2015-06-01 | 개시 | Citigroup | Buy |
| 2015-06-01 | 개시 | JP Morgan | Overweight |
모두보기
Atyr Pharma Inc 주식(ATYR)의 최신 뉴스
Holzer & Holzer, LLC Reminds Investors of Upcoming December - GlobeNewswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff - GlobeNewswire
Deadline Soon: aTyr Pharma Inc. (ATYR) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit - The AI Journal
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - PR Newswire
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Barchart.com
aTyr Pharma, Inc. $ATYR Shares Bought by Geode Capital Management LLC - Defense World
ATYR 5-DAY DEADLINE ALERT: Hagens Berman Urges aTyr Pharma Inves - GuruFocus
Shareholders SueWallSt in New Class Action Against aTyr Pharma, Inc.Act Now - Nasdaq
DEADLINE ALERT for ATYR, MLTX, BAX, JHX: Law Offices of Howard G. Smith Reminds Shareholders of Opportunity to Lead Securities Fraud Class Actions - GlobeNewswire Inc.
ATYR INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - GlobeNewswire
ATYR Deadline: ATYR Investors with Losses Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit - PR Newswire
Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - MarketScreener
Deadline Alert: aTyr Pharma Inc. (ATYR) Shareholders Who - GlobeNewswire
Shareholders that lost money on aTyr Pharma, Inc.(ATYR) should c - GuruFocus
Portnoy Law Firm Announces Class Action on Behalf of aTyr Pharma, Inc. Investors - GlobeNewswire
The Gross Law Firm Notifies aTyr Pharma, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineATYR - Lelezard
Will aTyr Pharma Inc. (471A) stock profit from fiscal stimulusQuarterly Risk Review & Low Volatility Stock Recommendations - Newser
How aTyr Pharma Inc. (471A) stock valuation compares with sectorMarket Trend Review & Consistent Profit Trading Strategies - Newser
ATYR 1-WEEK DEADLINE ALERT: Hagens Berman Urges aTyr Pharma Investors to Act by Dec. 8 Deadline in Suit Over Trial Failure - PR Newswire
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - MarketScreener
Bragar Eagel & Squire, P.C. Urgently Reminds Stockholders - GlobeNewswire
Lost Money on aTyr Pharma, Inc.(ATYR)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky - GlobeNewswire
aTyr Pharma Inc. (ATYR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securi - GuruFocus
Levi & Korsinsky Notifies aTyr Pharma, Inc. (ATYR) InvestorsLead Plaintiff Deadline on December 8, 2025 - Stockhouse
ATYR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that aTyr Pharma, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ATYR DEADLINE: Faruqi & Faruqi Reminds aTyr Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 8, 2025ATYR - PR Newswire
Shareholders of aTyr Pharma, Inc. (ATYR): Protect Your Rights Before December 8, 2025Contact Levi & Korsinsky - Stockhouse
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - GlobeNewswire
ATYR DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages - GlobeNewswire
ATYR Lawsuit: Hagens Berman Urges aTyr Pharma Investors to Act by Dec. 8 Deadline in Suit Over Trial Failure - Prime Publishers, Inc.
2025-11-28 | Securities Fraud Class Action Filed Against aTyr Pharma, Inc. (ATYR)Levi & Korsinsky Reminds Investors of December 8, 2025 | NDAQ:ATYR | Press Release - Stockhouse
ATYR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that aTyr Pharma, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ATYR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
ATYR INVESTOR NOTICE: Faruqi & Faruqi, LLP Announces that aTyr Pharma Investors Have Opportunity to Lead Class Action Lawsuit - MarketScreener
ATYR Deadline: ATYR Investors with Losses in Excess of $100K Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit - Your Wyoming Link
The Short List — Top 10 Most Shorted Stocks Right Now - Sahm
aTyr Pharma (ATYR) Securities Class Action Pending Over Key Drug's Efficacy -- Hagens Berman - GuruFocus
ATyr Pharma (ATYR) Securities Class Action Pending Over Key Drug's Efficacy -- Hagens Berman - MarketScreener
aTyr Pharma (ATYR) Securities Class Action Pending Over Key Drug's Efficacy — Hagens Berman - Morningstar
ATYR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that aTyr Pharma, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
aTyr Pharma (ATYR) Posts Wider-Than-Expected Loss as Investor Litigation Over Key Drug's Efficacy Moves ForwardHagens Berman - The Malaysian Reserve
aTyr Pharma, Inc. Sued for Securities Law Violations - GlobeNewswire
aTyr Pharma (ATYR) Posts Wider-Than-Expected Loss as Investor Litigation Over Key Drug's Efficacy Moves Forward -- Hagens Berman - Barchart.com
Recover Investment Losses: Class Action Initiated Against aTyr Pharma, Inc. (ATYR) - Stockhouse
aTyr Pharma Faces Class Action after Clinical Trial Failure Raises Investor Concerns - TipRanks
ATYR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that aTyr Pharma, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Shareholders that lost money on aTyr Pharma, Inc.(ATYR) Urged to - GuruFocus
Shareholders that lost money on aTyr Pharma, Inc.(ATYR) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - WV News
Traws Pharma Inc (TRAW) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - Setenews
You might want to take a look at Atyr Pharma Inc (ATYR) now - Setenews
Atyr Pharma Inc (ATYR) 재무 분석
Atyr Pharma Inc (ATYR)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Atyr Pharma Inc 주식 (ATYR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| SCHIMMEL PAUL | Director |
Oct 09 '25 |
Buy |
0.94 |
317,999 |
299,364 |
1,413,023 |
| Gross Jane A | Director |
Mar 17 '25 |
Buy |
4.00 |
3,750 |
15,000 |
9,750 |
| Broadfoot Jill Marie | Chief Financial Officer |
Feb 04 '25 |
Sale |
3.78 |
1,254 |
4,740 |
31,763 |
| DENYES NANCY | General Counsel |
Feb 04 '25 |
Sale |
3.78 |
899 |
3,398 |
26,555 |
0.50%
1.00%
자본화:
|
볼륨(24시간):